Navigation Links
Newer Drugs Beat Gleevec in Head-to-Head Trials
Date:6/5/2010

More chronic myeloid leukemia patients responded to Sprycel and Tasigna than Gleevec

SATURDAY, June 5 (HealthDay News) -- Two new drugs, dasatinib (Sprycel) and nilotinib (Tasigna), appear better than imatinib (Gleevec) in treating patients with newly diagnosed chronic myeloid leukemia and should be considered as first-line treatments, two new studies show.

The findings, which should change clinical practice, are to be presented Saturday at the American Society of Clinical Oncology annual meeting in Chicago and were simultaneously published online June 5 in the New England Journal of Medicine.

"Both next-generation inhibitors of BCR-ABL [dasatinib and nilotinib] are superior to Gleevec in treating chronic myeloid leukemia when compared head-to-head after one year of follow-up," said Dr. Charles L. Sawyers, chair of the Human Oncology and Pathogenesis Program at the Howard Hughes Medical Institute at Memorial Sloan-Kettering Cancer Center in New York City and author of an accompanying journal editorial.

"This magnitude of success -- beating a drug like imatinib [Gleevec] that was already pretty great -- is possible because we have a very precise understanding of the drug target BCR-ABL and of the mechanisms of resistance to imatinib," Sawyers added.

Newly diagnosed chronic myeloid leukemia patients should probably now be treated with one of the new drugs instead of imatinib, he noted.

In the first study, a team led by Dr. Hagop Kantarjian, chairman of the leukemia department at the University of Texas M.D. Anderson Cancer Center in Houston, randomly assigned 519 patients to Sprycel or Gleevec.

After a year, 77 percent of the patients receiving Sprycel had a complete cytogenetic response, compared with 66 percent of the patients receiving Gleevec, the researchers found.

Complete cytogenetic response is the disappearance of all the cancer cells from the bone marrow, Kanta
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan
2. Newer Drug More Effective in Psoriasis Treatment
3. Newer cornea transplant surgery shows short- and long-term promise
4. Newer Blood Test Predicts Diabetes, Heart Disease
5. Newer Genetic Test for Autism More Effective
6. Newer Blood Thinner Beats Plavix for Bypass Patients
7. Newer Genetic Info Adds Little to Predicting Breast Cancer
8. In infant heart surgery, newer technique yields better survival in first year of life
9. New Drugs, New Combinations Fight Breast Cancer
10. NICE guidelines ration affordable osteoporosis drugs
11. Bone Drugs May Beat Back Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2015)... (PRWEB) May 23, 2015 Javon ... at the Sports Medicine and Rehabilitation Center, 557 N. ... program, Mondays, June 1-July 20, 5:30-6:30 pm. , The ... coach, and Laurie Finke, RN, BSN, who will offer ... education on nutrition, running mechanics and show selection and ...
(Date:5/22/2015)... The world is at a "hinge ... to create new opportunities for leadership in health ... WesternU's 34th annual Commencement Exercises said Wednesday, May ... former San Francisco mayor and likely 2018 gubernatorial ... ceremony for WesternU's colleges of Allied Health Professions ...
(Date:5/22/2015)... Mountain Point Medical Center, a campus of Jordan Valley ... May 29, 2015 at 11 a.m., followed by a community ... center, set to officially open on June 1, 2015, is ... , “The opening of Mountain Point Medical Center is an ... said Kent Loosle, CEO of Mountain Point Medical Center. “Mountain ...
(Date:5/22/2015)... May 22, 2015 Following yesterday’s announcement ... agreement with US-based health brand Nature’s Way, Marc St-Onge ... Retention of Ascenta Skin is an integral part of ... about this opportunity to further develop Ascenta Skin into ... Ascenta Skin is a breakthrough, anti-aging skincare supplement featuring ...
(Date:5/22/2015)... NY (PRWEB) May 22, 2015 Hands ... that June 17, 2015, the Annual One Day Sale ... Since 2007, Hands On HCMT offers drastically reduced certificates one ... and estheticians have enough sessions, through what used to be ... is wonderful for the community as well. This once a ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3
... was,issued today by the law firms BERNSTEIN LITOWITZ BERGER & ... COURT NORTHERN DISTRICT OF CALIFORNIA SAN JOSE DIVISION, ... SECURITIES LITIGATION, Master File No. 99-CV-20743 RMW (PVT) ... To: ALL ACTIONS. TO: (1) ALL PERSONS AND ENTITIES ...
... being,issued by YouthAIDS:, WHAT: In March 2007, YouthAIDS Global Ambassador, ... Ashley Judd teamed up with Bollywood ... explore how HIV travels from high-risk groups to the ... young women are increasingly at risk for ...
... October 18, 2007 A clinical trial evaluating a ... cancer has begun at NYU Medical Center. The study ... therapy with surgery and chemotherapy in patients with glioblastoma ... The vaccine, called DCVax-Brain, incorporates ...
... the ... healthcare industry, OTTAWA, Oct. 19 /PRNewswire-FirstCall/ ... a 17-year,contract for the supply of cobalt-60 with Rosenergoatom, the operating,utility ... by providing for an increased supply of cobalt-60 to MDS,Nordion until ...
... Non-Steroidal Skin Treatment to Treat All ... Steroids, BARRINGTON, Ill., Oct. 19 Steroids have been ... There must be reasons why,people use steroid products on a ... organ of the human body, and it needs to stay ...
... VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH), a New ... targeted cancer therapeutics, announced today that it ... to VQD-002 (TCN-PM),and Lenocta(TM) (SSG) at the ... by the American Association for Cancer,Research (AACR), ...
Cached Medicine News:Health News:Summary Notice of Class Action in Re McKesson HBOC, Inc. Securities Litigation 2Health News:Summary Notice of Class Action in Re McKesson HBOC, Inc. Securities Litigation 3Health News:Summary Notice of Class Action in Re McKesson HBOC, Inc. Securities Litigation 4Health News:Summary Notice of Class Action in Re McKesson HBOC, Inc. Securities Litigation 5Health News:National Geographic Channel, Ashley Judd and YouthAIDS Host World Premiere Screening of 'India's Hidden Plague' 2Health News:Clinical trial evaluating brain cancer vaccine is underway at NYU 2Health News:MDS Nordion signs 17-year contract with Rosenergoatom 2Health News:Steroids Are Abused for Skin, Not Just Muscles 2Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 2Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 3Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 4Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 5
(Date:5/22/2015)... May 22, 2015 The North American ... and is estimated to reach $90.7 million by 2019, at ... Browse through the TOC of North America Dental Lasers Market ... help of various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... on this report.   Dental lasers are ...
(Date:5/22/2015)... 22, 2015  The U.S. Food and Drug ... the first biosimilar product approved in ... growth in the contract manufacturing organization (CMO) industry, ... is geared to the production of small-molecular drugs ... products. The healthcare market research publisher,s report, ...
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
Breaking Medicine Technology:North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
Surgitie&trade Single Use Ligating Loops without Delivery System with POLYSORB™....
ENDO SLIDE™ single use knot pusher with 12 units per box....
ENDO STITCH™ Single Use Loading Units....
ENDO STITCH™ Single Use Loading Units....
Medicine Products: